GRAPPAActive, not recruiting

GRAPPA

Gender
Women and men
Age
18 years and older
Trial type
Interventional
Line of therapy
Relapsed / refractory
Phase
Phase III

What is this trial about?

The GRAPPA study compares the use of two different medications to reduce the rate of graft-versus-host disease following a bone marrow transplant from an unrelated donor.

Detailed description

After a bone marrow transplant from an unrelated donor, there is a risk that the donor’s immune cells will attack the recipient’s tissue (known as “graft-versus-host reactions”). This can be one of the most serious side effects of a bone marrow transplant. As part of the study, a mixture of antibodies against lymphocytes—which has been the standard pre-transplant treatment—is being compared to the administration of chemotherapy (“post-transplant cyclophosphamide”) after the transplant. The latter is already being used successfully in a specific type of stem cell transplant.

Trial sites

26 trial sites in Germany are listed. Find a site near you.

  • Universitätsklinikum Aachen AöR

    Pauwelsstrasse 30, 52074 Aachen

    Status unknown

  • Universitätsklinikum Augsburg

    Stenglinstrasse 2, 86156 Augsburg

    Active, not recruiting

  • Klinikum Chemnitz gGmbH

    Chemnitz

    Status unknown

  • St. Johannes Hospital Dortmund

    Johannesstraße 9-13, 44137 Dortmund

    Status unknown

  • Universitätsklinikum Carl Gustav Carus Dresden

    Fetscherstrasse 74, 01307 Dresden

    Status unknown

  • Universitätsklinikum Düsseldorf

    Moorenstrasse 5, 40225 Düsseldorf

    Status unknown

This list is compiled to the best of our knowledge but without guarantee: it may be incomplete, and a site's recruitment status can change at any time.

Medical editorial team

  • Dr. med. Sebastian SommerSpecialist in internal medicine with a focus on hematology and oncology
  • PD Dr. med. Matthias FröhlichSpecialist in internal medicine, immunology and emergency medicine

This description is based on the public trial registry (NCT05153226) and was translated into plain language by our medical editorial team. Whether participation is an option for you is a decision you make together with your treating physician.